BIODELIVERY SCIENCES INTERNATIONAL INC Form 8-K October 27, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2010

BioDelivery Sciences International, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-31361 (Commission 35-2089858 (IRS Employer

of incorporation) File Number) Identification No.)


Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

801 Corporate Center Drive, Suite #210

Raleigh, NC 27607 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: 919-582-9050

Not Applicable

(Former name or former address, if changed since last report)



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Information.

On October 27, 2010, BioDelivery Sciences International, Inc. (the Company) issued a press release regarding a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration relating to the Company s BEMA Buprenorphine product candidate and the initiation of Phase 3 clinical trials for such product candidate. A copy of such press release is attached as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release, dated October 27, 2010, pertaining to a positive End-of-Phase 2 meeting with FDA regarding, and the initiation of Phase 3 clinical trials for, BEMA Buprenorphine.

Cautionary Note Regarding Forward-Looking Statements

This Report, the exhibit hereto and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the Company) related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company s plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, could, would, should, believes, expects, anticipates, estimates. plans, or These statements are based upon the current beliefs and expectations of the Company s management and are subject to significant risks and uncertainties, including those detailed in the Company s filings with the Securities and Exchange Commission. Actual results, including, without limitation, results of Phase 3 clinical trials for and regulatory review of BEMA Buprenorphine, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company s control). The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 27, 2010

BIODELIVERY SCIENCES INTERNATIONAL, INC.

By: /s/ James A. McNulty Name: James A. McNulty

Title: Secretary, Treasurer and Chief Financial Officer